NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology […]
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of RESOLVE-1 […]